Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  August 16, 2019

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Asthma, Allergic Disease, Passive Smoke Exposure & the Risk of RA

Arthritis & Rheumatology  |  August 7, 2019

Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. One hypothesis is that inflammation in the respiratory tract results in autoantibody formation that later leads to disease. Kronzer et al. set out to narrow the knowledge gaps related to the oral-respiratory factors that may mediate RA pathogenesis.

A More Complicated Pregnancy: Inflammatory Arthritis Increases the Risk for Adverse Outcomes

Arthritis Care & Research  |  August 2, 2019

Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…

RheumPAC Advocates for Department of Defense Arthritis Research Funding

Matt Baker, MD, MS  |  August 1, 2019

The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.

The Prevalence, Incidence, Mortality & Costs of RA-Related ILD

Kurt Ullman  |  July 18, 2019

Interstitial lung disease (ILD) can be associated with rheumatoid arthritis (RA) with significant morbidity and mortality. An article in The Journal of Rheumatology focused on calculating the prevalence, incidence, mortality and costs to the healthcare system of RA-related ILD (RA-ILD).1 “RA is the most common of connective tissue diseases encountered by rheuma­tologists—affecting about 1% of…

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Lara C. Pullen, PhD  |  June 25, 2019

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Eosinophilic Gastroenteritis & Eosinophilic Ascites Associated with RA

Helen Lyo, Eugene Han, MD, Shivakumar Vignesh, MD, & Nancy Soloman, MD  |  June 17, 2019

Eosinophilic gastroenteritis (EGE) is a rare condition caused by eosinophilic infiltration of the gastrointestinal (GI) tract. The condition is subdivided into the GI layers it affects: mucosal, muscular and subserosal.1 EGE usually presents with non-specific GI symptoms, such as impaired motility, intestinal obstruction and, rarely, ascites.2 Below, we report a rare case of EGE leading…

Biological DMARDs in Elderly RA Patients: Use, Maintenance & Discontinuation

Natasha Yetman  |  June 17, 2019

A study comparing seven biologic DMARDs in RA patients aged 65 years and older found abatacept had the highest retention rate and the lowest discontinuation rate…

New Research Examines the Use of Natural Dietary Supplements by RA Patients

Arthritis Care & Research  |  June 4, 2019

The popularity of natural dietary supplements has grown worldwide, with many adults using them to manage musculoskeletal conditions. But for RA patients, little is known about the risk of side effects and potential adverse drug interactions when taking these supplements with standard RA therapies. New research examined the supplement use patterns of RA patients…

Upadacitinib Monotherapy Effective in Refractory Rheumatoid Arthritis

Will Boggs MD  |  May 30, 2019

NEW YORK (Reuters Health)—Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results from the SELECT-MONOTHERAPY phase 3 trial. As many as two-thirds of patients with rheumatoid arthritis receiving methotrexate monotherapy fail to achieve satisfactory disease control. Oral therapy with upadacitinib…

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 74
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences